These findings suggest that targeting LRRK2 kinase activity may hold therapeutic promise for attenuating ER stress in LRRK2‐related PD, reinforcing the potential of LRRK2 kinase inhibitors as valuable therapeutic tools. The gene discussed is LRRK2; the disease is Parkinson disease.